US2008175839A1PendingUtilityA1

Compositions Against Cancer Antigen LIV-1 and Uses Thereof

68
Assignee: PROTEIN DESIGN LABS INCPriority: Mar 15, 1999Filed: Dec 21, 2007Published: Jul 24, 2008
Est. expiryMar 15, 2019(expired)· nominal 20-yr term from priority
Inventors:Debbie LawKurt GishRichard MurrayPatricia Culp
C12Q 2600/158C07K 16/3015C12Q 1/6886C07K 2317/73A61K 49/0002C07K 16/3069C12Q 2600/106A61K 2039/505A61K 49/0008G01N 33/5011C07K 14/4748A61P 43/00A61P 35/00G01N 33/57575G01N 33/57555G01N 33/57515A61K 39/0011A61K 39/00
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Claims

exact text as granted — not AI-modified
1 . A method of treating an individual with prostate or breast cancer, the method comprising administering an antibody that specifically binds to Liv-1. 
     
     
         2 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 1 , wherein the antibody is an antibody fragment. 
     
     
         4 . The method of  claim 1 , wherein the antibody is a humanized antibody. 
     
     
         5 . The method of  claim 1 , wherein the antibody is conjugated to an effector component. 
     
     
         6 . The method of  claim 5 , wherein the effector component is chosen from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical. 
     
     
         7 . The method of  claim 6 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         8 . The method of  claim 1  comprising administering the antibody with a pharmaceutically acceptable excipient.

Join the waitlist — get patent alerts

Track US2008175839A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.